Western Australian researchers have come up with a new drug (VX-770), which essentially reverses the abnormality caused by the cystic fibrosis mutation G551D. Patients treated with the new medication showed a significant and sustained improvement in lung function, a lower rate in pulmonary exacerbations and a reduction in sweat chloride and weight gain.
Prof Phil Thompson, Lung Institute of Western Australia
New England Journal of Medicine